UK man becomes first to receive customized cancer vaccine

UK man becomes first to receive customized cancer vaccine

In the United Kingdom, a man with the name, Graham Booth, who is battling a recurring head and neck cancer has received what physicians called a ‘cancer vaccine,’ on Tuesday.

Experts described the treatment as a major development in cancer research, is designed to train the individual’s body to recognise and defend the body from specific cancers.

According to a verified source, the vaccine treatment was designed specifically for this patient to prevent his cancer from recurring.

Although other cancer vaccines already exist, this specific injection is personalised to the person’s DNA.

The treatment, according to source Today, consists of a series of subcutaneous injections, which healthcare professionals deliver beneath the skin.

Although the trial is not yet over, experts say if it is successful, the vaccine will be groundbreaking in the field of cancer treatment.

Graham is a father of five children and lives in West Kirkby in the UK.

He first received a diagnosis of head and neck cancer in 2011, and, despite treatment, cancer returned four more times.

“When I had my first cancer treatment in 2011, I was under the impression that the cancer would not return,” says Graham.

“My biggest fear was realised in 2016 when it came back and then in 2019 and then two cases in 2021.

After Graham cancer returned in 2021, he began feeling hopeless.

However, he is now participating in the clinical trial to try to prevent his cancer from returning.

“Last year, I had the feeling of the cancer progressing, and there were not a lot of options left,” says Graham.

“This clinical trial has opened new doorways and gives me a bit of hope that my cancer won’t come back.

And this could open doorways for other people.

I’m hopefully looking at a brighter future.

A bit of hope that it never returns, which would mean the world to my family and everyone around me.


Christian Ottensmeier, professor of in minor oncology at the University of Liverpool and consultant medical oncologist at The Clatterbridge Cancer Centre, is overseeing the trial.

“It is a really exciting day in this important and potentially game-changing research,” says Dr.


Graham will receive more customised immunotherapy injections over the next year.

If the vaccine is successful, it will train his immune system to prevent the cancer from recurring.

“To have reached the stage of a patient receiving this treatment that only a few years ago was thought of as science fiction is truly amazing,” Ottensmeier said.

Although Graham is the first participant in this clinical trial, Dr.

Ottensmeier says that the researchers are adding more patients and hope that they will eventually be able to help people with other types of cancer.

“We are really grateful to Graham that he has agreed to participate in this clinical research trial,” says Dr.


“It is wonderful that we have been able to move from the theoretical stage of this research into creating a treatment for real people.

We have all waited so long for this day to come.

We think this will make a real difference to the patients we treat at Clatterbridge.

UK man becomes first to receive customized cancer vaccine